Jiong-Wei Wang,
Assistant Professor,
National University of Singapore
Jiong-Wei Wang received his Ph.D. in Medicine in 2013 from Leiden University Medical Centre (The Netherlands). After postdoctoral trainings in University Medical Centre Utrecht and National University of Singapore (NUS), he started his own laboratory as an Assistant Professor in 2019 at the NUS Department of Surgery, with joint appointments in Department of Physiology and the Cardiovascular Research Institute. He is also a Principal Investigator at the Nanomedicine Translational Research Programme. He has more than 80 publications and recently received the Wong Hock Boon Society–Singapore Medical Association (SMA) Charity Fund (WHBS-SMACF) Outstanding Mentor Award for 2019 and the NUS Yong Loo Lin School of Medicine Young Researcher of the Year Award for 2023. His research focuses on cardiovascular immunology, extracellular vesicles and nanomedicine drug delivery to develop more accurate diagnostics and more efficacious treatment approaches for cardiometabolic diseases. His laboratory has established various animal models of human diseases, including myocardial infarction, atherosclerosis and non-alcoholic fatty liver disease, for preclinical testing.
Targeting Hepatocytes with the Lipid Nanoparticular System in Fatty Liver Disease
Monday, 13 November 2023 at 15:00
Add to Calendar ▼2023-11-13 15:00:002023-11-13 16:00:00Europe/LondonTargeting Hepatocytes with the Lipid Nanoparticular System in Fatty Liver DiseaseExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Non-alcoholic fatty liver disease (NAFLAD) is a spectrum of chronic liver disease caused by excessive fat accumulation in the liver, with a prevalence of up to 40% in the United States and in Singapore. NAFLAD can develop into a more severe form, non-alcoholic steatohepatitis (NASH), characterized with liver inflammation and fibrosis, and ultimately cirrhosis and liver cancer. Currently, efficacious drugs reversing the various forms of this disease are not yet available. Here in this talk, I will discuss our recent study that employs the lipid nanoparticles (LNP) for targeted inhibition of a clinically relevant sphingolipid metabolic pathway in the hepatocytes with siRNA. With this LNP-siRNA approach, we achieved effective lowering of both hepatic and circulating ceramides and improved therapeutic indexes in animal models of non-alcoholic fatty liver disease. Apart from biochemical and histological evidence, the therapeutic efficacy was also confirmed by our recently developed myeloperoxidase-responsive MRI imaging. This proof-of-concept study demonstrates the feasibility of LNP siRNA system for the treatment of metabolic diseases.
Add to Calendar ▼2023-11-13 00:00:002023-11-14 00:00:00Europe/LondonExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023Extracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2023-11-13 15:00:002023-11-13 16:00:00Europe/LondonTargeting Hepatocytes with the Lipid Nanoparticular System in Fatty Liver DiseaseExtracellular Vesicles and Nanoparticle-based Therapeutics Europe 2023 in Rotterdam, The NetherlandsRotterdam, The NetherlandsSELECTBIOenquiries@selectbiosciences.com
